Immuneering's IMM-1-104, a pancreatic cancer therapy, receives FDA orphan drug designation.

Immuneering Corporation has received orphan drug designation from the FDA for IMM-1-104, an investigational therapy for pancreatic cancer. This designation may provide incentives like tax credits and marketing exclusivity. The drug is in a Phase 2a trial, showing promising initial results with a 40% overall response rate in pancreatic cancer patients when combined with chemotherapy. The company's shares rose over 20% following this news.

October 15, 2024
5 Articles

Further Reading